Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Randomized, Double-blind, Active Controlled, Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination FF/UMEC/VI With the Fixed Dose Dual Combination of FF/VI, Administered Once-daily Via a Dry Powder Inhaler in Subjects With Inadequately Controlled Asthma

Next Previous
Trial Profile

A Phase III, Randomized, Double-blind, Active Controlled, Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination FF/UMEC/VI With the Fixed Dose Dual Combination of FF/VI, Administered Once-daily Via a Dry Powder Inhaler in Subjects With Inadequately Controlled Asthma

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 13 Dec 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fluticasone furoate/umeclidinium/vilanterol (Primary) ; Vilanterol/fluticasone furoate (Primary) ; Salbutamol; Salmeterol/fluticasone propionate
  • Indications Asthma
  • Focus Registrational; Therapeutic Use
  • Acronyms CAPTAIN
  • Sponsors GlaxoSmithKline; GlaxoSmithKline Research & Development; GSK

    • Most Recent Events

    • 09 Nov 2022 Results assessing the relationship between Asthma Control Questionnaire (ACQ) scores and exacerbation rates, healthcare resource utilization (HCRU), and utility values in adults with moderate-to-severe asthma presented at the 25th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
    • 19 Oct 2022 Results assessing to explore potential differential treatment responses by examining asthma control (measured by the Asthma Control Questionnaire-6 [ACQ-6]) by age as a continuous variable in the CAPTAIN study, presented at the CHEST Annual Meeting 2022 by Annual Meeting of the American College of Chest Physicians.
    • 08 Nov 2021 Post-hoc analysis results d the impact of adding Umeclidinium and/or increasing Fluticasone Furoate dose in subgroups defined by baseline IgE levels, presented at the 2021 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top